ΛCCELERATED ΛCCESS COLLABORATIVE

**Programme Update for AAC Board
30 June 2021**

Programmes progressing well and work underway to align our AAC priorities and work programmes with NHSE exec teams

- **Key updates:**
  - **MedTech Funding Mandate** policy launched 1/4/2021. Supply Chain webpage completed. Analysis on 22/23 technologies started. Uptake trackers developed and reporting via the AHSN reporting tool QARTlive in development, ready for Q1 reporting (July 2021). **(See deep dive slide 9)**
  - **AI Award**: Review of Round 2 completed and agreed by AI Lab Board. Announcement on 16 June. Seven Round 1 evaluation scopes now approved by EAG. **(See deep dive slide 12)**
  - **Rapid Uptake Products** wave 3 process being designed with NICE (on agenda)
  - **Inclisiran** going through NICE and funding routes and mechanisms being agreed with DHSC and BSA (subject to a positive NICE TA)
  - Significant progress being made on **Innovation Service** and developer contract for private and public beta now confirmed **(See deep dive slide 6)**
  - Cross NHSE/I **Research Leadership Group** established, and survey started to map research or evaluation activity
  - New **metric** development for newly supported innovations underway.
  - **AHSNs -** regional prioritisation completed end March 2021. Funding for a new NHS Insight Prioritisation programme which supports an AHSN/Applied Research Collaborative partnership to evaluate innovations deployed during the pandemic confirmed as £4.2M. Business planning for NHSE/OLS and PSC commissions for AHSNs underway including new national programmes. 2023 relicensing of AHSNs consultation process to commence August 2021. AHSNs have commissioned an independent review of AHSN strategy which is due to report in September 2021.
  - AAC team led session with NHSE exec team on **Research and Innovation –** agreement link on ICS development and data sharing **(See deep dive slide 8)**
  - Cross NHSE/I **Research Leadership Group** established and survey started to map research or evaluation activity
  - **Horizon Scanning**: Revised remit and vision shifts focus onto more strategic proactive role for AAC horizon scanning function. AI scan and rapid polygenic risk scoring scan complete and limb internal fixation and HIT scans underway.
  - **Demand Signalling:** Report of Stroke Workshop being drafted. Planning underway for Mental Health and Learning Disability and Autism workshop 2. **(See deep dive slide 7)**

Patient and Public Involvement PPI
  - *Medtech Funding Mandate comms plan launched with 2 webinars delivered. .*RUPs: Comms assets in development, planning for events or roundtables. *IS: desktop research continues.*AI Award project 1 - comms assets in development. Patient and public attitudes to AI research underway, roundtables and interviews with stakeholders.
  - ATMP roundtable discovery event in May and July. *Histology Independent therapies workshop on 29th June.
  - Innovation Service: extensive comms planning underway, accessibility sense check with service users completed
  - Demand Signalling: planning underway and re-scoping for MH and learning disability and autism workshops.
  - Research: Comms stakeholder meeting 20 May, input to the research vision action plan, webinar on 18 May as part of the EPN conference.
  - VCSE Innovation during Covid project: report launched 19 May, webinar as part of EPN conference, strong coverage on social media

Delivery:

	AI Award	Late Stage support – AAC Rapid Uptake Products	Innovation Service	Horizon Scanning	Demand Signalling	Adoption & Spread	Early Stage Support – ATMPs and Tumour Agnostic Therapies	Research Resilience Programme	MedTech Funding Mandate
Current month (End Q1)	🟢	🟢	🟠	🟢	🟢	🟢	🟢	🟢	🟢
End of Q2	🟢	🟠	🟢	🟢	🟢	🟢	🟢	🟢	🟠

🟢 On track to deliver　🟠 Challenges to deliver, confident of mitigation actions　🔴 Significant risk to delivery and limited confidence in mitigations

Key delivery issues/risks:

Risk/issue	Likelihood	Impact	Mitigation
There is a risk that we will not be able to deliver the increasing levels of work and programmes being picked up within the team within our current team resources and HR panel declined additional resources	4	4	MW and business support following up with panel

Update from the Wider System
- The Life Sciences Council met on 10 May and agreed plans to develop a new Life Sciences Sector Vision as part of the Government's Plan for Growth. This will build on the successes of the 2017 Life Sciences Strategy. Work on the Health Innovation Manifesto will be wrapped into this.
- The Innovation Scorecard was published on 10 June and includes data on the 5 highest health gain categories.
- The next Healthtech Partnership meeting is due to take place on 6 July.
- The next Patient Access to Medicines Partnership meeting is due to take place on 10 September.

Significant communications and engagement activity across all our programmes

Communications & Engagement:

- The MedTech Funding Mandate policy went live on 1 April. Several of the supported products have subsequently featured widely in national media coverage including on the front page of The Times. We have held a number of sector facing events with in excess of 300 attendees.
- The second round of the AI in Health and Care Awards was announced by Secretary of State for Health and Social Care and round 3 launched at the end of June . Since the winners of the first round were announced every opportunity to raise the profile of the award has been sought, involving multiple engagement events via the AI Hub, social media spotlights with the Health Minister and each of the phase 4 round 1 winners and media coverage including the Financial Times and The New Stateman.
- Research, resilience and growth: In March with our partners we celebrated UK COVID-19 research passing one million participants. We worked with Sir Simon Stevens to publish a thank you video ; working with trusts locally to encourage a wider thank you campaign directed towards staff.
- We also supported the launch of Saving and Improving lives: The Future of UK Clinical Research Delivery and the follow up implementation plan. Deputy Director of Research Ali Austin published a blog to engage frontline staff and has since spoke at NHS Confed 2021 on how we can work together to improve diversity in clinical trial participation. On 20 May we celebrated International Clinical Trials day and alongside the Chief Nursing Officer we supported #Red4Research day.
- AAC Rapid Uptake Products (RUPs): Engagement leads have been developing comms and engagement plans for all products. For example Tamoxifen on World Cancer Day (4 Feb) and FeNO testing and Biologics on World Asthma Day (5 May). This has involved working with third sector partners to help promote the RUPs.
- We worked with National Voices to commission 'Unlocking the digital front door: keys to inclusive healthcare' The report, which focused on how to work with voluntary and community sector to develop digital health care solutions, was launched at an online event with health care professionals in May
- Alongside the Beneficial Changes Network the AAC published a report on the impact on COVID-19 on the Innovation and Research landscape..
- We supported the delivery of two sector facing events focussed on tackling CVD and healthcare inequalities across the UK through a population health management approach, featuring Inclisiran. Also in partnership the AHSN Network and Heart UK we launched the first in a series of webinars as part of the Tackling Cholesterol Together education programme.

Future Priorities:

- Increasing the efficiency of **research** undertaken in the NHS to ensure we attract the world's best research studies and give the maximum number of people an opportunity to participate in these studies. Ensure the research undertaken in the NHS answers questions that are important to patients and NHS staff.
- Develop a pipeline of high impact **AI** products which will be ready for system adoption testing with 1-2 years and facilitate initial systems adoption of leading AI technologies into the NHS.
- Understand funding implications for **MedTech Funding Mandate** (MFM) options, working with Costing and Pricing team, NICE, Strategic finance, Supply Chain and legal. Design a four-year programme for MFM.
- Closure of **Test Beds** programme complete July 2021
- Announce and sign contracts with **AI Award** Round 2 awardees
- **AI Award** Round 3 launched on 29 June
- Development of first 'evaluation learning' publication on **AI study design**
- Develop agreed route for **Inclisiran** commercial model and confirm mechanisms for maintaining price anonymity
- Support for **restarting/resilience of research** in NHS
- Agreeing process for **commercial deal triage**
- Complete **stage 1 of adoption and spread mapping** work and plan engagement as part of stage 2
- Finalise delivery model for **Innovation Service** including hosting and management function

Delivery metrics 2020-21 financial year Q1-Q4 (1 Apr to 31 Mar 2021)

AAC Scorecard Home

Programme: (All)

Period ending: 2020-21 Q4

NHS

3,474 innovators are being worked with

3,722 innovations are receiving support (3,700 early stage, 22 late stage)

Estimated patient benefits include:
17,328 fewer admissions to hospital
142,339 fewer days spent in hospital

327,836 patients accessing our innovations
37% of eligible patients

762 sites accessing our innovations
57% of eligible sites

£119.0M of in-year savings to the health system

£271.4M of investment secured

1,361 jobs created or safeguarded (763 created, 597 safeguarded)

Measures of innovation not attributable to the AAC

Notes:
1. Metrics for the newly supported wave 2 Rapid Uptake Products have been developed and will be reported in the AAC Scorecard from 2021-22 Q1.
2. The number of patients accessing our innovations and in-year savings to the health system both exclude the Atrial Fibrillation (AF) programme. Data for AF are sourced from the annual Quality and Outcomes Framework, which has not yet been published for 2020-21. AF has a sizeable patient population but is cost incurring in-year, so once included the number of patients will increase but savings will decrease.
3. The value of investment secured and number of jobs exclude the Clinical Entrepreneurs programme due to the impact of COVID-19 on programme and survey timings. In addition, the Small Business Research Initiative (SBRI) survey remains open to allow additional responses – with its contribution therefore provisional and requiring further validation by the programme.

Appendix – programme deep dives

- **Single Front Door for Innovators: Innovation Service**
- **Demand Signalling: Demand Signalling Update**
- **Research: Research Work Programmes**
- **Agreed Funding Strategy: MedTech Funding Mandate**
- **Single Horizon Scanning Approach: Early Stage Categories**
- **Single Horizon Scanning Approach: Vision and Progress**
- **World-leading Testing Infrastructure: AI in Health and Care Award**
- **NHS Export Collaborative**

Single front door for innovators:
NHS Innovation Service (previously 'Portal')

Programme Aims
Create a "single front door" to the innovation ecosystem, envisaged as an online service with information, support, and signposting that links to existing teams providing detailed advice on aspects of the innovation pipeline.

Key Programme Updates

Information for innovators
- Basic guide for early stage innovators seeking publishing approvals. Advanced guide being finalised, aimed at later stage innovators or those seeking more detailed information.
- Two case studies have been completed and will add real examples to the content. Five more are underway, including four with innovators with protected characteristics.

Development
- Our developers have delivered a development environment, ability to create accounts and sign in, landing page, accessor homepage, innovators dashboard, triage questions
- We will run a private beta trial of the system in July and August to test it with a sample of users (accessor organisations and innovators)

Stakeholders
- Workshops with accessor organisations have identified the requirement for a 'needs assessment' team who will take an initial look at new innovations registering on the NHS Innovation Service and direct them to the most appropriate organisation.
- The Innovation Service Senior Level Steering Group agreed that the name should be the 'NHS Innovation Service'

User research to date
- 1:1 and workshop sessions held with early and late-stage innovators, accessors and those with accessibility needs to test prototypes and content

Timelines / Upcoming Milestones
- Private beta testing July and August 2021
- GDS beta assessment at end of August 2021 followed by transition to public beta if successful
- Run public beta and add additional functionality in Autumn
- Close entry to Health Tech Connect and redirect to NHS Innovation Service when service is running smoothly, likely Autumn 2021
- Formal launch in autumn/winter 2021

Demand Signalling: Update

Programme Aims To work with multi-disciplinary stakeholders including clinicians, academics and those with lived experience to articulate the priority research needs and innovation challenges to deliver on ambitions set out in the Long-Term Plan. Research questions will then be signalled out to funders, and innovation challenges will be signalled out to innovators.

Key Programme Updates

- The **Stroke** Demand Signalling second workshops took place in February, and we are currently in the process of finalising the report, as well as an internal 'lessons learnt' report. A meeting with NIHR took place in May to discuss best approaches to take individual research questions forward. The outcome was that the NIHR (NETSCC, CCF and DHSC SRE) are pleased with progress and keen to build a programme of work around the outputs (where applicable). The next steps are to arrange monthly 'funder' meetings to further iterate and develop.

- **Learning Disability and Autism**: We held a roundtable on 9 June with a mixed stakeholder group from the Learning Disability and Autism programme that confirmed that the priority areas identified from workshop 1 are still relevant and agreed next steps in process. A report is being drafted

- For the **Mental Health** work programme, we are currently working with workshop leads for each of the priority areas identified in workshop 1 to undertaken an evidence appraisal. Multi-disciplinary stakeholders will be asked to develop research questions and innovation challenges based on the identified evidence gaps, which will be considered in the workshop 2 series due to take place in July.

- We are planning to commence engagement with the other Long Term plan priority areas to initiate the Demand Signalling process with them once the new team members are in post.

- The team are currently recruiting to vacant Project Support Officer and Research Officer posts.

Timelines / Upcoming Milestones
- On-boarding of new Project Support Officer and Research Officer from July onwards
- Stroke Reports released by 28th June
- Mental Health workshop 2 series scheduled w/c 5th July

Research:
Research Work Programmes

COLLABORATIVE logo: ∆CCELERATED ∆CCESS COLLABORATIVE

Programme Aims

Improving patient outcomes by embedding research in healthcare practice across all NHS settings, and increasing the number and diversity of people accessing and taking part in research.

Key Programme Updates

Summary of current research Activity

- Recruitment to UHP Covid Platform trials (eg RECOVERY, REM-CAP and PRINCIPLE) has fallen significantly with under 50-80 people recruited a week compared to around 4,000 a week at the height of wave 2. This is in line with falling numbers of cases and hospital admissions due to COVID
- There is a continuing need to recruit people into the PRINCIPLE community based COVID research study, particularly as we explore the benefits of licenced antivirals to treat Covid early.
- Recruitment to non-Covid research remains low at around 7000 people a week but numbers of trials restarting is slowly increasing.

Research Resilience and Growth Programme

- Cross sector programme initially aimed at supporting the restart of non-Covid research in NHS, with initial focus on commercial and key non-commercial studies
- National Research Vision published on 23 March -https://www.gov.uk/government/publications/the-future-of-uk-clinical-research-delivery. Very high level which sets out 5 key themes and 7 actions including the ambition to embed research in the NHS.
- Implementation will be 2 phased, with the first phase focusing on 2021/22 activity to support recovery of research activity. Phase 1 published 23 June The Future of UK Clinical Research Delivery: 2021 to 2022 implementation plan - GOV.UK (www.gov.uk)
- NIHR has published an update relating to managing research recovery for non-COVID studies over the next 6 to 12 months. DHSC has publish Managed Recovery Guidance https://www.nihr.ac.uk/documents/guidance-on-the-managed-recovery-of-the-uk-clinical-research-portfolio/27749

Cross NHSE/I Research Leadership Group

- A cross NHSE/I level Group has been set up, for the first time bringing together teams across the organisation who have links to research and evaluation. This group is helping to shape the National Vision Implementation Plan
- A mapping exercise is underway that will give real clarity on what research/evaluation NHSE/I commissions and how we are supporting research in NHS

Timelines / Upcoming Milestones

- National Implementation Plan published 23 June 2021
- 1st of RRG working groups for 7 actions set out in vision established in June
- NHSE/I mapping excise complete and internal report drafted July 2021
- NHSE/I research/evaluation plan/framework drafted September 2021 (internal or external doc tbc

Agreed funding strategy:
MedTech Funding Mandate

Programme Aims

The MedTech Funding Mandate aims to accelerate the uptake of selected NICE approved cost-saving medical devices, diagnostics and digital products in the NHS by making their use a contractual requirement for providers and commissioners– meaning patients will get access to these technologies faster.

Key Programme Updates

MedTech Funding Mandate (MTFM) Policy and Guidance:
- MTFM policy guidance 2021/22 and consultation report documents now published the AAC MTFM webpage here
- MTFM policy 2021/22 became effective on the 1st April 2021
- MTFM policy briefing webinars were held on the 20th April and the 4th May, reaching an audience of around 280
- NHS E National Media Team publishing press articles on individual technologies supported by the MTFM with huge success
- Work to understand visibility of use of innovations in mandated national datasets commenced

Next steps:
- Collaborate with NICE to identify list of eligible technologies to be supported by the MTFM in 2022/23
- Publish a signalling document to the sector by 31st July listing the eligible technologies to be supported by the MTFM in 2022/23
- Work with analytical resource to ensure the progress of MTFM is fully captured and reported
- Continue working closely with NHS England National Tarif Pricing Team to understand Aligned Incentive Payment System proposed for 2022/23

Engagement with NHS Supply Chain on MedTech Funding Mandate products
- Products were available to purchase from NHS Supply chain on 1st April launch.
- NHS Supply Chain dedicated MTFM webpage now live

Next steps:
- Working with NHS Supply Chain to finalise reporting to NHS England to understand uptake
- Work with NHS Supply Chain once 2022/23 technologies are identified

Engagement with suppliers supported by the MTFM 2021/22
- MedTech Funding Mandate Action Learning Set Group continues to meet to discuss programme and overcome challenges faced in transition as a team
- Individual 121 weekly meetings held with suppliers to help with transition from ITP to MedTech Funding Mandate

Timelines / Upcoming Milestones

June: Understand which technologies meet the 2022/23 MTFM criteria, engage with stakeholders on them and carry out analysis to understand current adoption and spread.
Continue to support the technologies supported by the 2021/22 MTFM policy.
Support National Tariff Pricing Team on engagement for an Aligned Incentives Payment Scheme.
July: Publish signalling document to the sector in readiness for 2022/23 MTFM.

Single Horizon Scanning Approach: Early Stage Categories

Programme Aims

The AAC Board agreed in June 2019 to provide support two categories of early stage products; Advanced Therapy Medicinal Products (ATMPs) and Histology Independent Therapies (HITs) to accelerate their adopting into the NHS by addressing key barriers identified for these categories of products.

Key Programme Updates

Following significant impact of the pandemic on delivery during 20/21, the programme has been re-established and is now delivering effectively across both HITs and ATMPs. Our current focus remains on the delivery of agreed commitments and work plans for the existing products and demonstrating success of the progamme, including the impact of AAC partner support. The exit strategy for the programme has been developed and will be piloted as workstreams reach completion. Once the new Deputy Director of Accelerated Access Collaborative is in post (expected late summer) we will begin to progress plans and timelines for agreeing the second wave of early stage support and welcome discussions with AAC partners to refine the process and criteria for a second tranche of products when we initiate this work.

ATMP and HIT Workstream highlights:
- The ATMP Patient & Public Involvement & Engagement (PPIE) working group has been set up to coordinate and collaborate on PPIE activities to support adoptions of ATMPs in the NHS. Lived experience and patient and public voice representatives have been recruited.
- The HIT refresh horizon scan is complete, the output of the scan will be used to inform the future planning of the work programme.
- EY have been successfully appointed by ABPI to develop the ATMP roadmap to support companies to navigate the route to NHS adoption for ATMPs and project initiated.
- The Data Infrastructure workstream (WS5) has been re-established, scope and deliverables have been agreed and membership of the working group broadened. Topics for 'deep-dive' pathfinders (candidates for managed access) have been agreed and engagement is underway
- The 2nd stage of the NICE methods review is under way.
- Development of the Innovative Medicine Fund (IMF) principles are on-going, listening events with patient groups and industry have taken place and public engagement events planned.
- The Commercial Framework for New Medicines was published in February 21.
- The ILAP has delivered the objectives for workstream 9. Since the launch in January, 31 innovation passport applications have been received and 1 Target Development Profile, exceeding expectations. Close down of WS9 has been initiated
- Phase 2 of NTRK gene fusion testing is ongoing. The Genomics Programme Board has approved additional pathology workforce requirements to support the increased volume of NTRK gene fusion testing, plans for implementation underway. Patient engagement workshop to understand awareness of HIT planned end of June
- NICE cancer guidance and pathways for HITs have been published and close down of WS12 has been initiated

Next Steps:
- Finalise success measures for the early stage programme
- Pilot and refine exit strategy with WS9 & WS12
- Develop AAC early stage communications strategy

Timelines / Upcoming Milestones
- HIT Patient engagement workshop – Jun 21
- ATMP horizon scan refresh start – June 21
- Consultation on the 2nd stage of the NICE Methods review (ATMP & HIT) – Aug 21
- Public engagement on the Innovative Medicine Fund (IMF) principles - imminently

Single Horizon Scanning Approach : Vision and Progress

ACCELERATED ACCESS COLLABORATIVE

Programme Aims
The central Horizon Scanning team will support the adoption of new technologies into the NHS identifying future innovations for the NHS early so ensuring challenges are identified and planned for.

Key Programme Updates
- In collaboration with stakeholders, a Horizon Scanning vision is being developed to introduce a more strategic focus to how Horizon Scans are undertaken. Clinicians and commissioners will be included in working groups to ensure there is an understanding of what disruptive technology means in their area and consideration is given to the impact the introduction of an innovation will have on the pathway, as well as procurement of the technology.
- Developing strategic intelligence through Horizon Scanning will help underpin our commercial and policy decision making.

Completed scans
Artificial Intelligence (AI): to understand which products are currently being used in the UK on a research or commercial basis and which providers and using which products
Polygenic Risk Scoring: rapid scan to understand competitive landscape for these technologies

On-going scans
Direct skeletal fixation: scan to gather information on implants and connectors to understand the efficacy and cost of each direct skeletal fixation procedure
Histology Independent Therapies (HIT) targeted at cancer: help AAC partners plan for the introduction of increased genomic testing, infrastructure and capability by understanding the current HIT status
Radioligand Therapy: to gather information on the current pipeline of radioligand therapy and molecular radiotherapy to inform strategic planning of these services going forward
Aerosol generating procedures (AGP) in pulmonary function testing: To identify technologies to prevent/mitigate the risks associated with aerosol generation during respiratory function testing, particularly spirometry.

Planned scans
Advanced Therapy Medicinal Products (ATMPs): gather information on the ATMPs landscape up to 2026 to help AAC partners plan for introduction of these into the NHS.
Antimicrobial resistance (AMR): to understand what AMR technology is currently in the pipeline

Timelines / Upcoming Milestones
- Develop an implementation plan and test our new Horizon Scanning vision.
- Delivery of the Histology Independent Therapies scan to the Early Stage Programme which will inform the future planning of the work programme.

World-leading Testing Infrastructure:
AI in Health and Care Award

Programme Aims

To establish the UK as the preeminent destination for developing and scaling health and care AI solutions by:

1. Funding leading AI innovators to develop their technologies in UK
2. Building a world-class real-world AI testing infrastructure in UK
3. Accelerating adoption and spread of proven AI technologies across NHS

Key Programme Updates

Round 1

- Round 1 Competition Winners announced in Sept 2019; contracting with winners complete and a total of c.£55m funds committed
- Round 1 technologies have deployed to >80 sites, with this number set to reach >100 by the end of Summer
- Focus on adoption and spread mapping for the 10 Phase 4 winners to develop a clear pathway to local commissioning in the context of the development of ICSs

Evaluation

- 7/10 evaluation scopes agreed by the AI Award Evaluation Advisory Group and research projects mobilised. 2 further scopes to be agreed by June. Final scope paused until Winter 21.
- Selection process agreed for evaluators for competition 2 went live on 17/05. Will enable 'pool' of Evaluation Partners to draw down from for final competitions.
- Plan for the development of 'evaluation learning' documents agreed: two publications on (1) AI study designs (2) Challenges and solutions in relation to execution of AI evaluations in 21/22

Round 2-4

- 366 applications submitted for Comp 2, with Winners ratified by AI Lab Board Richard.Winstanley@NHS.netRichard.Winstanley@NHS.net
- Round 2 Winners announced on 16 June
- Round 3 to open 29 June 2021

Programme

- Team fully recruited but further resource requested in business planning to deliver more ambitious programme in 21/22
- We have received a number of positive press articles in national newspapers profiling AI Award winners and the work of AAC
- Two key projects are planned for this year: a PPIE in AI research programme due to report in June 2021 and a research piece exploring access to risk capital for AI developers due to report in Sept 21.
- AI Award team are exploring opportunities to support 1) NHS elective recovery work (eg use cases for PTL risk stratification). 2) Development of Community Diagnostics Hubs

Timelines / Upcoming Milestones

- Round 1 evaluations to start (Q1 21/22)
- Round 2 Winners announced by SoS 16 June
- Round 3 opens (June 2021)
- Completion of AI study Design review (June 2021)

NHS Export Collaborative

Programme Aims

As promised in the NHS Long Term Plan, the NHS Export Collaborative is being established to make it easier and more productive for NHS organisations to collaborate in exporting NHS innovations and healthcare expertise.

Key Programme Updates

- Following an extensive period of engagement, the operating model for the NHS Export Collaborative has been co-developed with NHS family exporters, ensuring that the new support will add most value.

- Conversations with NHS leaders involved in exporting have highlighted the wide-ranging support for the initiative and the benefits to the NHS of international engagement as part of its recovery, post Covid-19. Wider benefits include research and learning, staff engagement, recruitment and retention as well as additional income, which is ploughed back into local NHS services.

- Healthcare UK in the Department for International Trade, is to host the NHS Export Collaborative in recognition of its existing network of international relationships. This will mean that the support for exports is in a dedicated unit and enables the NHS to retain its focus on core service priorities. The arrangements have been agreed by the tripartite Executive Steering Group – which comprises NHS England and NHS Improvement, the Department for Health and Social Care and the Department for International Trade.

- NHS England and NHS Improvement has identified funding in 2021/22 to establish an initial team which team will support NHS family organisations, including trusts, Arms-Length Bodies, CSUs and AHSNs to respond to the rising overseas demand for NHS innovations and expertise through collaborative offers. Recruitment started at the end of May 2021, with a view to the team becoming operational from September 2021.

- Healthcare UK will continue to promote the UK health sector, provide access to overseas networks and maintain the current level of bespoke export support currently offered to NHS family organisations.

Timelines / Upcoming Milestones

- End May - Recruitment started
- Sept - Initial team to become operational